MDS Inc. and Danaher Corporation Receive Second Request for Information from U.S. Federal Trade Commission for MDS Analytical Technologies Sale

MDS Inc. and Danaher Corporation Receive Second Request for Information
from U.S. Federal Trade Commission for MDS Analytical Technologies Sale

TORONTO, and WASHINGTON, D.C., Nov. 3 /PRNewswire-FirstCall/ - MDS Inc. (TSX:
MDS; NYSE: MDZ), a leading provider of products and services to the global
life sciences markets, and Danaher Corporation (NYSE: DHR), a diversified
technology leader, today announced that they have each received a Second
Request for information from the Federal Trade Commission (FTC) regarding the
sale of MDS Analytical Technologies.
The Second Request relates to a global market segment that MDS and Danaher
estimate generates less than $50 million in annual revenues for all sellers
combined.
The information request was issued under notification requirements of the Hart
Scott Rodino Antitrust Improvements Act of 1976, as amended (HSR Act). The
effect of the Second Request is to extend the waiting period imposed by the
HSR Act for a period of 30 calendar days from the date of the parties'
substantial compliance with the request, unless the waiting period is earlier
terminated.
MDS Inc. and Danaher Corporation continue to cooperate with the FTC and
currently expect the transaction, which was announced on September 2, 2009 and
received approval from MDS shareholders on October 20, 2009, to close before
the end of the first calendar quarter of 2010, subject to the satisfaction of
the conditions to closing.

About Danaher Corporation

Danaher is a diversified technology leader that designs, manufactures, and
markets innovative products and services to professional, medical, industrial,
and commercial customers. Our portfolio of premier brands is among the most
highly recognized in each of the markets we serve. Driven by a foundation
provided by the Danaher Business System, our 50,000 associates serve customers
in more than 125 countries and generated $12.7 billion of revenue in 2008. For
more information, please visit our Website: www.danaher.com

About MDS Inc.

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides
market-leading products and services that customers need for the development
of drugs and diagnosis and treatment of disease. MDS Inc. is a leading global
provider of pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has more than
3,600 highly skilled people in 13 countries. Find out more at www.mdsinc.com
or by calling 1-888-MDS-7222, 24 hours a day.

SOURCE MDS Inc.

MDS CONTACTS: MEDIA: Janet Ko, (905) 267-4226, janet.ko@mdsinc.com; INVESTORS:
Peter Dans, (905) 267-4230, peter.dans@mdsinc.com; DANAHER CONTACT: MEDIA AND
INVESTORS: Matt McGrew, (202) 828-0850, matt.mcgrew@danaher.com